Skip to main content

Chennai: Malaria vaccine awaits clinical trials


The vaccine created by the team of scientists, which has completed the pre-clinical trial (animal experimenting), will induce an immune response comprising of antibodies.

However, the menace continues to prevail, causing diseases like malaria and dengue.
The vaccine created by the team of scientists, which has completed the pre-clinical trial (animal experimenting), will induce an immune response comprising of antibodies.
 
The vaccine created by the team of scientists, which has completed the pre-clinical trial (animal experimenting), will induce an immune response comprising of antibodies.
Chennai: Fogging and using mosquito coils and nets are only a few among various methods many use to protect themselves from mosquitoes.

However, the menace continues to prevail, causing diseases like malaria and dengue. Therefore, as a means to check malaria transmission, a team of scientists from New Orleans, USA, has invented a vaccine targeting the sexual development of malaria parasites in the mosquito vector.

Vector-borne diseases account for 17 per cent of the estimated global burden of all infectious diseases, according to reports of the World Health Organisation (WHO), and are a major public health problem, particularly in tropical and sub-tropical regions. Some of these diseases are fatal if not treated, while others leave patients disfigured and disabled.

The vaccine created by the team of scientists, which has completed the pre-clinical trial (animal experimenting), will induce an immune response comprising of antibodies. "When a mosquito bites a human being, it will pick up parasites mixed along with the antibodies.

The antibodies will prevent the parasites from further developing," said head of the team, Prof. Nirbhay Kumar, Professor of Tropical Medicine and Director of the Vector Borne Infectious Diseases centre, Tulane University, New Orleans, US, at the sidelines of the 13th conference on vector and vector borne diseases, jointly organized by the National Academy of Vector Borne Diseases, with the Central University of Tamil Nadu.

ᐧ

Comments

Post a Comment

Popular posts from this blog

ICH GCP requires EC members to be independent of investigator and sponsor to avoid conflicts of interest

Can an Ethics Committee member e.g. layman/chairman or anyone in the committee participate in the trial as a subject? Vidya If an Ethics Committee member becomes a trial subject on a trial that he/she was involved in approving then there has been a major conflict of interest. The following situations need to be considered: ● IEC member reviews study without any prior knowledge of the study, votes, and then afterwards is approached by clinical research team to participate. Possibly this is OK but the member should no longer be part of the IEC that reviews that study. This will be difficult in practice, so therefore it is not advisable. ● IEC member already knows about the study and is voting in order to be able to participate. This is clearly not acceptable and made worse if there is additional financial incentive for the study (e.g. volunteer study). ICH GCP requires Ethics Committee members to be independent of the investigator and the sponsor to avoid confl...
Post a Comment
Read more

BE guidelines regarding investigator

BE guidelines recommend investigator should possess appropriate medical qualification, experience for conducting pharmacokinetic studies Can chairperson of EC directly write to sponsor to clarify some of the queries of clinical trial raised in EC meeting? Dr. Sreevatsa Please see an extract from FDA's comment on IRB-sponsor relationship. The interrelationship and interaction between the research sponsor (e.g., drug, biologic and device manufacturers), the clinical investigator and the Institutional Review Board (IRB) may be very complex. The regulations do not prohibit direct sponsor-IRB contacts, although, the sponsor-IRB interaction customarily occurs through the investigator who conducts the clinical study. The clinical investigator generally provides the communication link between the IRB and the sponsor. Such linkage is agreed to by the sponsors and investigators when they sign forms FDA-1571 and FDA-1572, respectively, for drug and biologic studies or a...
Post a Comment
Read more

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris...
Post a Comment
Read more